This section contains information about Galapagos NV’s business for stockholders, potential investors, financial analysts and media.
Do you want to receive our press releases?
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription…
BCA’s national network of blood centers will provide decentralized manufacturing services for Galapagos’ CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment…
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunology Executed agreements with…
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary…
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)…
Publication of annual report for financial year 2023 Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board members Extraordinary Shareholders’…
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board…
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7…
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February…
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca®…
Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-of-care CAR-T product candidate in the San Francisco area Agreement follows previously announced…
Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ expertise in small molecule drug discovery and…